Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: Clinical significance

AIDS Research and Human Retroviruses

Volumn 26, Issue 3, 2010, Pages 293-300

  Rowley, Christopher F ^a,b,c   Boutwell, Christian L ^b   Lee, Esther J ^b,c   MacLeod, Iain J ^b   Ribaudo, Heather J ^d   Essex, M ^c   Lockman, Shahin ^b,c,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Harvard AIDS Institute   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

BOTSWANA; DRUG RESISTANCE, VIRAL; FEMALE; GENE FREQUENCY; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; NEVIRAPINE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950285125     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0082     Document Type: Article

References (32)

1. UNAIDS: 2008. Report on the Global HIV=AIDS Epidemic 2008. Geneva: UNAIDS.
2. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, and Jackson JB: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
3. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang- Huong N, Koetsawang S, Kanshana S, McIntosh K, and Thaineua V: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV- 1 in Thailand. N Engl J Med 2004;351:217-228.
4. Ayouba A, Tene G, Cunin P, Foupouapouognigni Y, Menu E, Kfutwah A, Thonnon J, Scarlatti G, Monny-Lobe M, Eteki N, Kouanfack C, Tardy M, Leke R, Nkam M, Nlend AE, Barre-Sinoussi F, Martin PM, and Nerrienet E: Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaounde, Cameroon. J Acquir Immune Defic Syndr 2003;34:274-280.
5. Stringer JS, Sinkala M, Chapman V, Acosta EP, Aldrovandi GM, Mudenda V, Stout JP, Goldenberg RL, Kumwenda R, and Vermund SH: Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS 2003; 17:1659-1665.
6. Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, Nour S, Chen S, Liomba G, Miotti PG, and Broadhead RL: Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: A randomized controlled trial. JAMA 2004;292:202-209.
7. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, and Jackson JB: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
8. Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, and Jackson JB: Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004;20:595-599.
9. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, and Taha T: Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005;19:2167-2169.
10. Toni TD, Masquelier B, Lazaro E, Dore-Mbami M, Ba-Gomis FO, Tea-Diop Y, Kouakou K, Diby J, Sia E, Soppi S, Essien S, Schrive MH, Pinson P, Chenal H, and Fleury HJ: Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-tochild transmission. AIDS Res Hum Retroviruses 2005;21: 1031-1034.
11. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, and Lallemant M: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-240.
12. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, and Essex M: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147.
13. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, and Grant RM: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-480.
14. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, and Eshleman SH: Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006;8:430-432; quiz 527.
15. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, and Eshleman SH: Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005;192:24-29.
16. Lecossier D, Shulman NS, Morand-Joubert L, Shafer RW, Joly V, Zolopa AR, Clavel F, and Hance AJ: Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005;38:37-42.
17. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, and Heneine W: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005;192:16-23.
18. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, and Morris L: Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce motherto- child HIV transmission. AIDS 2006;20:995-1002.
19. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, Mellors J, Morris L, and Coffin J: Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006;103:7094-7099.
20. Kullsiek KH, Peng G, Simen B, Simons J, Egholm M, Novak R, MacArther R, and Kozal M: Virologic success of different strategies for initial ART regimens is predicted by the type and detection level of minor drug-resistant variant detected by ultra deep sequencing: The CPCRA 058 FIRST study. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3-6, 2008. Abstract 878.
21. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, and Heneine W: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008;5:e158.
22. Paredes R, Lalama C, Ribaudo H, Schackman B, Shikuma C, Meyer W, III, Giguel F, Squires K, Gulick R, and Kuritzkes D: Presence of minor populations of Y181C mutants detected by allele-specific PCR and risk of efavirenz failure in treatment-naive patients: Results of an ACTG 5095 casecohort study. 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3-6, 2008. Abstract 83.
23. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, and Kuhn L: Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009;48:462-472.
24. Johnson V, Brun-Vezinet F, Clotet B, Gunthard H, Kuritzkes D, Pillay D, Schapiro J, and Richman D: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.
25. Rowley CF, Boutwell CL, Lockman S, and Essex M: Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C. J Virol Methods 2008;149:69-75.
26. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT, Jr., Dewar RL, Metcalf JA, Hammer S, Mellors JW, and Coffin JM: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005;43:406-413.
27. Bergroth T, Sonnerborg A, and Yun Z: Discrimination of lamivudine resistant minor HIV-1 variants by selective realtime PCR. J Virol Methods 2005;127:100-107.
28. Mellors J, Palmer S, Nissley D, Kearney M, Halvas E, Bixby C, Demeter L, Eshleman S, Bennett K, Hart S, Vaida F, Wantman M, Coffin J, and Hammer SftASG: Low-frequency NNRTI-resistant variants contribute to failure of efavirenzcontaining regimens. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8-11, 2004. Abstract A39.
29. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, Stevens L, Heymann SJ, Ndung'u T, Gaseitsiwe S, Novitsky V, Makhema J, Lagakos S, and Essex M: Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006;20:1281-1288.
30. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, and Kahn JO: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
31. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, and Richman DD: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
32. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, and Alexander L: Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004;78:603-611.